tiprankstipranks
Advertisement
Advertisement

BMEA Stock Latest News

Biomea Fusion doses first patient in COVALENT-211, COVALENT-212 trials
The FlyBiomea Fusion doses first patient in COVALENT-211, COVALENT-212 trials
2d ago
BMEA
Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’
PremiumThe Fly
Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’
6d ago
BMEA
Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes
PremiumThe Fly
Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes
17d ago
BMEA
Biomea Fusion management to meet virtually with Craig-Hallum
PremiumThe Fly
Biomea Fusion management to meet virtually with Craig-Hallum
28d ago
BMEA
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline
PremiumCompany Announcements
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline
1M ago
8K
BMEA
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference
PremiumCompany AnnouncementsBiomea Fusion Highlights Diabetes Pipeline at JPM Conference
3M ago
8K
BMEA
Biomea Fusion initiated with a Buy at Rodman & Renshaw
Premium
The Fly
Biomea Fusion initiated with a Buy at Rodman & Renshaw
3M ago
BMEA
Biomea Fusion enters 2026 focused on icovamenib, BMF-650 milestones
Premium
The Fly
Biomea Fusion enters 2026 focused on icovamenib, BMF-650 milestones
3M ago
BMEA
Biomea Fusion announces KOL presentation
PremiumThe Fly
Biomea Fusion announces KOL presentation
4M ago
BMEA
Biomea Fusion presents COVALENT-111 study results at WCIRDC
PremiumThe Fly
Biomea Fusion presents COVALENT-111 study results at WCIRDC
4M ago
BMEA
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan
PremiumThe Fly
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan
5M ago
BMEA
Biomea Fusion price target lowered to $6 from $7 at Citi
PremiumThe Fly
Biomea Fusion price target lowered to $6 from $7 at Citi
5M ago
BMEA
Biomea Fusion announces presentation of two posters for BMF-650, icovamenib
PremiumThe FlyBiomea Fusion announces presentation of two posters for BMF-650, icovamenib
5M ago
BMEA
Biomea Fusion price target lowered to $12 from $16 at D. Boral Capital
Premium
The Fly
Biomea Fusion price target lowered to $12 from $16 at D. Boral Capital
5M ago
BMEA
Biomea Fusion Inc. Reports Q3 2025 Financial Results
Premium
Company Announcements
Biomea Fusion Inc. Reports Q3 2025 Financial Results
5M ago
BMEA
Biomea Fusion reports Q3 EPS (27c), consensus (29c)
PremiumThe Fly
Biomea Fusion reports Q3 EPS (27c), consensus (29c)
5M ago
BMEA
BMEA Earnings this Week: How Will it Perform?
PremiumPre-Earnings
BMEA Earnings this Week: How Will it Perform?
5M ago
BMEA
Biomea Fusion’s BMF-650: A New Hope in Obesity Treatment?
PremiumCompany Announcements
Biomea Fusion’s BMF-650: A New Hope in Obesity Treatment?
5M ago
BMEA
Biomea Fusion’s BMF-219 Trial for Type 1 Diabetes: A Terminated Phase 2 Study
PremiumCompany Announcements
Biomea Fusion’s BMF-219 Trial for Type 1 Diabetes: A Terminated Phase 2 Study
5M ago
BMEA
Biomea Fusion announces first patient dosed in Phase I trial of BMF-650
PremiumThe FlyBiomea Fusion announces first patient dosed in Phase I trial of BMF-650
5M ago
BMEA
Biomea Fusion’s Promising Clinical Trials and Strategic Advancements Drive Buy Rating
Premium
Ratings
Biomea Fusion’s Promising Clinical Trials and Strategic Advancements Drive Buy Rating
6M ago
BMEA
Positive Outlook for Biomea Fusion: Promising Phase 2 Results for Icovamenib in Type 2 Diabetes Treatment
Premium
Ratings
Positive Outlook for Biomea Fusion: Promising Phase 2 Results for Icovamenib in Type 2 Diabetes Treatment
6M ago
BMEA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >